A Pilot Study on Proteomic Predictors of Mortality in Stable COPD
Proteomic predictors of mortality in COPD and their connection to respiratory, cardiovascular, and cancer-related deaths
Can Proteomic Predictors of Mortality Help Forecast Outcomes in Stable COPD?
Most of the long-term deaths are attributable to respiratory causes, with lower percentages attributed to cardiovascular/cerebrovascular events or cancer.
It is worth nothing that a trend toward better prognoses (disease progression, exacerbations, and mortality) has been observed in the last few years.
This phenomenon may be due to recent changes in treatment and involves the need for new studies on the current predictors of mortality.
Studying proteomic predictors of mortality in COPD to improve survival prognosis
Therefore, the objective of this pilot study was to identify proteomic markers and specific multiprotein signatures that could be useful in predicting long-term mortality, identifying the related pathways and contributing to our knowledge on the mechanisms linked to a poor prognosis for COPD patients.
Proteomic predictors of mortality in COPD: Understanding the biological mechanisms involved in future deaths in long-term patients
A proteomic blood signature found in stable COPD patients can help in establishing their long-term (4-year) survival prognosis.
The most important elements for establishing this prognosis are proteins/peptides linked to the hemostatic and inflammatory statuses during the stable phase, as well as different elements of the immune response.
Furthermore, the present results may help us to better understand the biological mechanisms involved in future deaths in long-term patients.
Authors
Cesar Jessé Enríquez-Rodríguez, Carme Casadevall, Rosa Faner, Sergi Pascual-Guardia, Ady Castro-Acosta, José Luis López-Campos, Germán Peces-Barba, Luis Seijo, Oswaldo Antonio Caguana-Vélez, Eduard Monsó, Diego Rodríguez-Chiaradia, Esther Barreiro, Borja G. Cosío, Alvar Agustí, Joaquim Gea and on behalf of the BIOMEPOC Group
Read more details at
Fecha de publicación
Published: 14 August 2024
Categorías asociadas al artículo
Noticias relacionadas
The ROME COPD exacerbation proposal works! Time to move forward
The ROME proposal for COPD exacerbations classification offers a new approach to assess severity and predict outcomes, improving clinical decision-making
COPD Management in Primary Care: Underutilisation of Nursing Consultations
Analysis of COPD management in primary care highlighting the role and underutilisation of nursing consultations and healthcare utilisation patterns in real-world patients.
Joint statement from GOLD/GLI regarding the use of spirometry to define airflow obstruction and diagnose COPD
Joint GOLD/GLI statement on spirometry to define airflow obstruction and confirm COPD diagnosis, aiming to harmonize criteria and improve global practice.
cfDNA profiling in COPD
Whole-genome cfDNA profiling identifies molecular clusters and pathways associated with oxidative damage and airflow limitation in COPD patients.
Exploring the association between eosinophils and autoimmunity in COPD
Study exploring the association between eosinophils and circulating autoantibodies in COPD patients, considering airflow limitation and smoking status.
ECLIPSE: un estudio de tres años que cambió nuestra forma de entender la EPOC
A 20 años de ECLIPSE, repasamos el estudio que transformó la comprensión de la EPOC, revelando su heterogeneidad, progresión y biomarcadores clave.
Imagen desarrollada DALL·E, Canva y Diseño gráfico